# Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

> **NCT00712166** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 160 (actual)

## Conditions studied

- Cystic Fibrosis
- Lung Infection
- Pseudomonas Aeruginosa

## Interventions

- **DRUG:** AZLI 75 mg three times daily (TID)
- **DRUG:** Placebo three times daily (TID)

## Key facts

- **NCT ID:** NCT00712166
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-08
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2010-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00712166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00712166, "Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00712166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*